COMP <GO>
APYX vs MRK // ENTERPRISE SCALE & MARKET CAP
Apyx Medical Corporation (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: APYX 1
— MRK 10
▲ ENTERPRISE SCALE & MARKET CAP LEADER: MRK
LAST: $2.60 (-3.35%) • MKT CAP: $113.3M
market-cap
$113.3M
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
market-cap
$361.02B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APYX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APYX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.50% | 74.80% | -12.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -28.90% | 20.70% | -49.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.04% | 3.42% | -11.46 | MRK | /fcf-yield <GO> |
| Operating Margin | -12.20% | 34.30% | -46.50 | MRK | /operating-margins <GO> |
| Net Profit Margin | -21.20% | 28.10% | -49.30 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 9.90% | 1.30% | +8.60 | APYX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.75 | 5.19 | -4.44 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.1 | 51.7 | -2.55 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $113.3M | $361.02B | -$360.91B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APYX REV | MRK REV | APYX GROSS % | MRK GROSS % | APYX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $52.8M | $65.01B | 62.5% | 74.8% | -$9.1M | $12.36B |
| FY 2024 | $48.1M | $64.17B | 61.0% | 76.3% | -$18.8M | $18.10B |
| FY 2023 | $52.3M | $60.12B | — | — | -$5.2M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APYX // BETA —
MRK // BETA 0.92